ARS Pharmaceuticals Expands Executive Leadership Team with Addition of Pharmaceutical Commercialization Veterans

 SAN DIEGO - February 09, 2022 – ARS Pharmaceuticals, Inc., a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced the expansion of its executive leadership team with the appointments of Harris Kaplan as executive...

ARS Pharmaceuticals, Inc. to Share New Data at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

Data will highlight patient outcomes of pharmacokinetics, pharmacodynamics, and safety of neffy™ (ARS-1), with simple intranasal epinephrine administration and other epinephrine intramuscular injection devicesSAN DIEGO - February 2, 2022 – ARS Pharmaceuticals, Inc., will share new data on neffy highlighting our innovative intranasal treatment of type 1 severe allergic reactions...

ARS Pharmaceuticals Raises $55 Million in Series D Funding for Launch Preparations of Neffy™ (epinephrine nasal spray)

San Diego, Calif. – August 31, 2021 – ARS Pharmaceuticals, Inc., a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions potentially leading to anaphylaxis, has closed on a Series D financing of $55 million led by SR One with participation from...

ARS Pharmaceuticals Strengthens Board of Directors with Appointment of Industry Leader and Innovator Brent Saunders

SAN DIEGO – May 13, 2021 – ARS Pharmaceuticals, Inc., a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions potentially leading to anaphylaxis, today announced the appointment of biotech leader and visionary Brent Saunders to its Board of Directors. Mr. Saunders...

ARS Announces Acceptance of Market Authorization Application submission to European Medicines Agency for Neffy (ARS-1; epinephrine nasal spray)

SAN DIEGO, November 23, 2020 – ARS Pharmaceuticals (ARS) announced today that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application (MAA) submission for review of NeffyTM (ARS-1; epinephrine nasal spray) an epinephrine nasal spray for the emergency treatment of severe allergic reactions, including anaphylaxis. This follows ARS’...